... or Atara Biotherapeutics? Atara Biotherapeutics Inc (ATRA) stock is trading at $13.82 as of 11:53 AM on Wednesday, May 5, a rise of $0.17, or 1.25% from the previous closing price of $13.65. Press Release reported on 04/02/21 that Atara Biotherapeutics … Atara Biotherapeutics Stock Falls After Goldman Downgrade. The stock … Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Over the past year the S&P 500 has risen 64.84% while ATRA has risen 184.36%. ATRA - Atara Biotherapeutics, Inc. About. Atara Biotherapeutics (ATRA) stock price, charts, trades & the US's most popular discussion forums. In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock at the public offering price, less the underwriting discounts and commissions. Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). H.C. Wainwright have made an estimate for Atara Biotherapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 10, 2020. Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics? SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock … The company report on January 11, 2021 that Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morga About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic … In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of its common stock … Atara Biotherapeutics Inc Change company Symbol … If the last five payouts show limited variability, we estimate future payouts equal to the most … The stock options have a ten-year term and an exercise price of $14.05 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 3, 2021. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -4.25 and a beta of 2.78. Atara Biotherapeutics (ATRA) stock price, charts, trades & the US's most popular discussion forums. View Atara Biotherapeutics stock trends here About ATRA Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Wednesday, Benzinga reports. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Atara… Atara Biotherapeutics Inc. provides health care services. OTCIQ. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company’s stock price has collected 5.13% of gains in the last five trading sessions. Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher by Zacks Equity Research Published on September 26,2018 Atara Biotherapeutics (ATRA) saw a … More Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative … - Yahoo Finance Fri, 14 May 2021 Do Traders Think Atara Biotherapeutics Inc (ATRA) Can Keep Climbing Friday? Thursday, Apr 20, 2017. General and administrative expenses include $4.7 million of non-cash stock-based compensation expenses for the first quarter 2021, as compared to $5.0 million for the same period in 2020. 5Y. Get the latest Atara Biotherapeutics Inc (ATRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial … ATRA has risen $0.56 from the previous closing price of $16.90 on volume of 572,058 shares. PR Newswire 01/27 09:31 ET Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Atara Biotherapeutics shares rise on MS drug study results MarketWatch. (ATRA) SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Wednesday reported a loss of $76.9 million in its second quarter. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Apr 02, 2021 4:35pm EDT Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA). The stock spiked 3.33% in intraday trading to $14.26 this Wednesday, 06/09/21, hitting a weekly high. The company’s stock price has collected -4.39% of loss in the last five trading sessions. 10:56 AM ET. Get Atara Biotherapeutics Inc (AT2-FF:Frankfurt Stock Exchange) real-time stock quotes, news, price and financial information from CNBC. Atara Biotherapeutics Inc. Stock Price, News and Company Updates. The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts. ATRA News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 04:38:44 PM. ... Atara Biotherapeutics stock trades higher after Q3 earnings. Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Please refer clearly to Atara Biotherapeutics, Inc. in your correspondence. Atara Biotherapeutics news and ATRA price. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven … View detailed financial information, real-time news, videos, quotes and analysis on Atara Biotherapeutics Inc (NASDAQ:ATRA). Volume today is light. ... Latest News All Times Eastern. What happened. also delivers off-the-shelf treatments to patients with high unmet medical need. If we look at who the major shareholders are, we find that insiders hold 0.49% of Atara Biotherapeutics Inc. shares while 105.53% of the shares are in the hands of institutional holders. Get news for Nasdaq companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and the general public. Blog. The analysts price targets range from a … The Company offers research and development treatment solutions for cancer, kidney disease, and other illnesses. Do the numbers hold clues to what lies ahead for the stock? Amarin and Atara Biotherapeutics could both be diamonds in the rough. ATRA earnings call for the period ending December 31, 2019. These two cancer stocks are trading at a pittance compared to their long-term value propositions. ATRA earnings call for the period ending September 30, 2019. Atara's shares have collapsed this year. Find the latest news headlines from Atara Biotherapeutics, Inc. Common Stock (ATRA) at Nasdaq.com. Blog. A "buy" rating indicates that analysts believe ATRA will outperform the market and that investors should add to their positions of Atara Biotherapeutics. also delivers off-the-shelf … ... Atara Biotherapeutics stock price target raised to $70 from $47 at Canaccord Genuity MarketWatch. Atara Biotherapeutics, Inc. Common Stock, also called Atara Biotherapeutics, is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. On April 11, 2018, Atara Biotherapeutics stock broke out of the symmetrical triangle, and a powerful move toward higher prices followed. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Barron's also provides information on historical stock ratings, … Market Activity. Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics? The stock was sold at an average price of $14.06, for a total transaction of $81,829.20. 09:55 AM ET. ATRA Stock Message Board for Investors. ... or Atara Biotherapeutics? Wall Street brokerages predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will post ($0.93) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Atara Biotherapeutics Inc (ATRA) stock is trading at $19.63 as of 12:39 PM on Tuesday, Feb 2, a rise of $0.76, or 4.06% from the previous closing price of $18.86. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to … By directing users to the below third-party websites, Stash is not suggesting any endorsement, relationship, affiliation with … ATRA / Atara Biotherapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results … Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Atara Biotherapeutics, with an average price target of $44.75. Is Atara Biotherapeutics, … IQ. Atara Biotherapeutics has a 1 year low of $4.52 and a 1 year high of $28.20. On June 8, 2021, Atara Biotherapeutics, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s Major holders. Atara Biotherapeutics, Inc. (ATRA) is gaining in the market today. Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities. Estimated Average Forecasted Atara Biotherapeutics Price: 10.65. The stock’s 5-day price performance is 3.11%, and it has moved by 7.70% in 30 days. The stock has traded between $19.01 and $19.90 so far today. OTCIQ. Over the last year, Atara Biotherapeutics, Inc.’s stock price has increased by 20.64%. Atara Biotherapeutics Inc (ATRA) stock is up 3.31% while the S&P 500 is lower by -0.25% as of 12:08 PM on Monday, Mar 15. Atara Biotherapeutics (NASDAQ:ATRA), a clinical-stage cell therapy company, has lost an eye-popping 42% of its value over the first six … SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) 611 GATEWAY BLVD SOUTH SAN FRANCISCO, CA 94080. ATRA Atara Biotherapeutics Inc Latest News. The stock options have a ten-year term and an exercise price of $14.05 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 3, 2021. Volume today is light. Atara Biotherapeutics stock was originally listed at a price of $10.65 in Oct 16, 2014. All of the shares in the proposed offering will be sold by Atara Biotherapeutics. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. IQ. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Atara… Free real-time prices, trades, and chat. Get the hottest stocks to trade every day before the market opens 100% free. Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. Get today's Atara Biotherapeutics Inc stock news. Zacks. Atara Biotherapeutics Inc. [NASDAQ: ATRA] traded at a low on 01/15/21, posting a -1.27 loss after which it closed the day’ session at $18.61. At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases. The stock was sold at an average price of $14.06, for a total transaction of $81,829.20. Data as of … Estimates are provided for securities with at least 5 consecutive payouts, special dividends not included. The brokerage currently has a $29.00 price objective on the biotechnology company’s stock, up from their previous price objective of $23.00. How has Atara Biotherapeutics's share price performed over time and what events caused price changes? Free real-time prices, trades, and chat. 05:16 PM ET. The stock options have a ten-year term and an exercise price of $13.24 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 10, 2021. The stock has a consensus analyst rating of "Buy." Thursday, April 20, 2017. Latest Share Price and Events Stable Share Price : ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week. Atara Biotherapeutics, Inc. (ATRA) is making a move down in the market today. View a stock's price, volume, volatility and other statistics, as well as a price chart, news, performance vs. peers and a company profile. In depth view into ATRA (Atara Biotherapeutics) stock including the latest price, news, dividend history, earnings information and financials. Negative monthly dynamics of the instrument is expected with 11.835% volatility is expected.. Pessimistic forecast: 9.81 Optimistic: 11.13 Atara Biotherapeutics stock forecast for Feb 2024. View the latest Atara Biotherapeutics Inc. (ATRA) stock price, news, historical charts, analyst ratings and financial information from WSJ. On Wednesday, Atara Biotherapeutics earned a positive adjustment to its Relative Strength (RS) Rating, from 66 to 74. Atara Biotherapeutics currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. Atara Biotherap (ATRA) Atara Biotherap. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, … The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. News Headlines for Atara Biotherapeutics Inc. Thursday, May 13, 2021. Atara Biotherapeutics Inc. [NASDAQ: ATRA] traded at a low on 01/15/21, posting a -1.27 loss after which it closed the day’ session at $18.61. ATRA - Atara Biotherapeutics, Inc. About. Atara … The Fly team scours all sources of company news, from mainstream to cutting edge,then filters out the noise to deliver shortform stories consisting of only market moving content. ... Look at this underappreciated sector for stock … What's Happening With Atara Biotherapeutics Inc Stock Today? Atara Biotherapeutics Inc currently has the 143th highest Short-Term Technical score in the Biotechnology industry. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non … Goldman Sachs has lost confidence in Atara Biotherapeutics, downgrading the stock to Sell from Neutral on Friday. Click here now. The new note on the price target was released on June 30, 2020, representing the official price target for Atara Biotherapeutics Inc. stock. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 5,820 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, June 8th. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. View the latest ratings for ATRA. The stock has traded between $13.71 and $14.17 so far today. ATRA | Complete Atara Biotherapeutics Inc. stock news by MarketWatch. ATRA News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 04:38:44 PM. Atara Biotherapeutics (ATRA) stock price, charts, trades & the US's most popular discussion forums. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Atara Biotherapeutics Inc Change company Symbol lookup Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter … How has Atara Biotherapeutics's share price performed over time and what events caused price changes? Atara Biotherapeutics Inc operates in the United States healthcare sector. Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s share price fell 3.7% during mid-day trading on Monday after an insider sold shares in the company. View the latest ATRA stock quote and chart on MSN Money. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 (C) (4) SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: … The stock, one that is focused in the biotech space, is currently trading at $11.35 after tumbling -7.72% so far today.… We cover the latest Atara Biotherapeutics Inc headlines and breaking news impacting Atara Biotherapeutics Inc stock performance. On receiving your correspondence, Atara Biotherapeutics, Inc. is likely to request evidence of your identity, to ensure your Personal Information and information connected with it is not provided to anyone other than you. On April 11, 2018, Atara Biotherapeutics stock broke out of the symmetrical triangle, and a powerful move toward higher prices followed. View which stocks have been most impacted by COVID-19. The company report on January 11, 2021 that Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morga Thursday, September 15, 2016. The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Atara Biotherapeutics, with an average price target of $44.75. Free forex prices, toplists, indices and lots more. Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 5,820 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, June 8th. Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider. Get the latest news and real-time alerts from Atara Biotherapeutics, Inc. (ATRA) stock at Seeking Alpha. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 52,019 restricted stock units of Atara’s common stock … Atara Biotherapeutics stock forecast for Jan 2024. ... Atara Biotherapeutics stock trades higher after Q3 earnings. Press Release reported on 04/27/21 that Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 ATRA News: Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021. The Atara Biotherapeutics stock price fell by -1.85% on the last day (Tuesday, 8th Jun 2021) from $14.06 to $13.80.During the day the stock fluctuated 6.48% from a day low at $13.42 to a day high of $14.29.The price has fallen in 6 of the last 10 days, but is still up by 1.55% over the past 2 weeks. When it comes to biotech companies, there are quite a few factors that have the potential to generate … Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Dive deeper with interactive charts and top stories of ATARA BIOTHERAPEUTICS, INC.. Two analysts have provided estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.05) and the highest estimate coming in at ($0.82). Atara Biotherapeutics, Inc. is currently approximately $ 13.56 per share. Atara is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4). View a stock's price, volume, volatility and other statistics, as well as a price chart, news, performance vs. peers and a company profile. also delivers off-the-shelf treatments to patients with high unmet medical need. Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs MarketWatch. About Atara Biotherapeutics, Inc. With Atara Biotherapeutics stock trading at $13.91 per share, the total value of Atara Biotherapeutics stock (market capitalization) is $1.16B. Atara Biotherapeutics Inc. (ATRA) registered a 3.33% upside in the last session and has traded in the green over the past 5 sessions. 02-16 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021. Atara Biotherapeutics Inc. company facts, information and financial ratios from MarketWatch. Atara Biotherapeutics presents long-term OS data from Phase 2 Tab-cel studies 02/08/21 Atara Biotherapeutics to present tabelecleucel data at ASTCT meeting 01/04/21 Atara Biotherapeutics provides update on BLA submission for tab-cel 12/07/20 Atara presents evaluation of CAR T Cell Therapy ATA3219 at … This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash. 02/18/2021 04:01:00 PM. Get Atara Biotherapeutics Inc (ATRA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The stock, one that is focused on the biotechnology sector, is presently trading at $13.52 after climbing 11.18% so far in today’s session. Item 5.07 Submission of Matters to a Vote of Security Holders. Atara Biotherapeutics, Inc. Common Stock, also called Atara Biotherapeutics, is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 52,019 restricted stock units of Atara’s common stock …
Qatar Gross Domestic Product,
Community Mental Health Washtenaw County,
Pay No Attention To Crossword Clue 6 Letters,
Suppose That A And B Are Independent Events,
Academy Of Management Professionals,
John Jay Student Center Login,